 Poly(ADP-ribose) Polymerases
"Poly(ADP-ribose) Polymerases" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Enzymes that catalyze the transfer of multiple ADP-RIBOSE groups from nicotinamide-adenine dinucleotide (NAD) onto protein targets, thus building up a linear or branched homopolymer of repeating ADP-ribose units i.e., POLY ADENOSINE DIPHOSPHATE RIBOSE.
| Descriptor ID |
D011065
|
| MeSH Number(s) |
D08.811.913.400.725.115.690
|
| Concept/Terms |
Poly(ADP-ribose) Polymerases- Poly(ADP-ribose) Polymerases
- Poly(ADP-ribose) Polymerase
- Poly ADP Ribose Polymerase
- Poly ADP Ribose Transferase
- Poly(ADP-Ribose) Synthase
- Poly(ADP-Ribose) Transferase
- Poly(ADPribose) Polymerase
- Poly(ADPR) Polymerase
- Poly ADP-Ribose Synthase
- Poly ADP Ribose Synthase
- Synthase, Poly ADP-Ribose
- ADP-Ribosyltransferase (Polymerizing)
- PARP Polymerase
- Polymerase, PARP
Nuclear ADP Ribose Transferases- Nuclear ADP Ribose Transferases
- ADP-Ribosyltransferase, Nuclear
- ADP Ribosyltransferase, Nuclear
- Nuclear ADP-Ribosyltransferase
- Nuclear ADP Ribosyltransferase
- Nuclear ADPRT
- ADPRT, Nuclear
- Nuclear Adenosine Diphosphoribosyltransferase
- Adenosine Diphosphoribosyltransferase, Nuclear
- Diphosphoribosyltransferase, Nuclear Adenosine
- Nuclear NAD+ ADP-Ribosyltransferase
- ADP-Ribosyltransferase, Nuclear NAD+
- NAD+ ADP-Ribosyltransferase, Nuclear
- Nuclear NAD+ ADP Ribosyltransferase
|
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerases".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerases".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerases" by people in UAMS Profiles by year, and whether "Poly(ADP-ribose) Polymerases" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2024 | 1 | 0 | 1 | | 2023 | 0 | 1 | 1 | | 2021 | 0 | 1 | 1 | | 2020 | 0 | 1 | 1 | | 2019 | 0 | 1 | 1 | | 2018 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2016 | 0 | 1 | 1 | | 2015 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2013 | 1 | 1 | 2 | | 2011 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2007 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2003 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 1997 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerases" by people in Profiles over the past ten years.
-
Bhandari SK, Wiest N, Sallmyr A, Du R, Tomkinson AE. Redundant but essential functions of PARP1 and PARP2 in DNA ligase I-independent DNA replication. Nucleic Acids Res. 2024 Sep 23; 52(17):10341-10354.
-
Mittra A, Coyne GHOS, Zlott J, Kummar S, Meehan R, Rubinstein L, Juwara L, Wilsker D, Ji J, Miller B, Navas T, Ferry-Galow KV, Voth AR, Chang TC, Jiwani S, Parchment RE, Doroshow JH, Chen AP. Pharmacodynamic effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. Cancer Chemother Pharmacol. 2024 03; 93(3):177-189.
-
Sadhukhan R, Ghosh U. PARP1 modulates telomere sister chromatid exchange and telomere length homeostasis by regulating telomere localization of SLX4 in U2OS cells. Life Sci. 2021 Jul 15; 277:119556.
-
Das KC, Muniyappa H, Kundumani-Sridharan V, Subramani J. Thioredoxin Decreases Anthracycline Cardiotoxicity, But Sensitizes Cancer Cell Apoptosis. Cardiovasc Toxicol. 2021 02; 21(2):142-151.
-
Houl JH, Ye Z, Brosey CA, Balapiti-Modarage LPF, Namjoshi S, Bacolla A, Laverty D, Walker BL, Pourfarjam Y, Warden LS, Babu Chinnam N, Moiani D, Stegeman RA, Chen MK, Hung MC, Nagel ZD, Ellenberger T, Kim IK, Jones DE, Ahmed Z, Tainer JA. Selective small molecule PARG inhibitor causes replication fork stalling and cancer cell death. Nat Commun. 2019 12 11; 10(1):5654.
-
Urbaniak A, Delgado M, Antoszczak M, Huczynski A, Chambers TC. Salinomycin derivatives exhibit activity against primary acute lymphoblastic leukemia (ALL) cells in vitro. Biomed Pharmacother. 2018 Mar; 99:384-390.
-
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E. Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 2017 03 01; 28(3):512-518.
-
Qiang YW, Ye S, Chen Y, Buros AF, Edmonson R, van Rhee F, Barlogie B, Epstein J, Morgan GJ, Davies FE. MAF protein mediates innate resistance to proteasome inhibition therapy in multiple myeloma. Blood. 2016 12 22; 128(25):2919-2930.
-
Philchenkov AA, Zavelevich MP, Tryndyak VP, Kuiava LM, Blokhin DY, Miura K, Silvestri R, Pogribny IP. Antiproliferative and proapoptotic effects of a pyrrole containing arylthioindole in human Jurkat leukemia cell line and multidrug-resistant Jurkat/A4 cells. Cancer Biol Ther. 2015; 16(12):1820-9.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|